Evidence map›Paper›PMID 21964595›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2011

Negative cross talk between NFAT1 and Stat5 signaling in breast cancer.

Jiamao Zheng, Feng Fang, Xianke Zeng, Terry R Medler, Alyson A Fiorillo, Charles V Clevenger

Abstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.Progress in molecular biology and translational science · 2017
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. NFAT as cancer target: mission possible?Biochimica et biophysica acta · 2014
    Review
  10. Article
  11. NFAT gene family in inflammation and cancer.Current molecular medicine · 2013
    Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jiamao ZhengWomen’s Cancer Research Program, Robert H. Lurie Comprehensive Cancer Center & Department of Pathology, Northwestern University, Chicago, Illinois 60611, USA.
Feng Fang
Xianke Zeng
Terry R Medler
Alyson A Fiorillo
Charles V Clevenger
Northwestern University · USRobert H. Lurie Comprehensive Cancer Center of Northwestern University

Funding

PROLACTIN RECEPTOR COMPLEX IN BREAST CANCERR01CA069294 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CLEVENGER, CHARLES V · 1996 to 2006
$1.9M
Regulation of Stat Function in Breast CancerR01CA102682 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CLEVENGER, CHARLES V · 2003 to 2007
$1.3M
NCI NIH HHS CA102682NCI NIH HHS CA69294NCI NIH HHS R01 CA069294NCI NIH HHS R01 CA102682
6 · The paper itself

Abstract

The molecular mechanisms that modulate the activity of the signal transducers and activators of transcription 5 (Stat5) during the progression of breast cancer remain elusive. Here, we present evidence that the calcineurin/nuclear factor of activated T cells (NFAT) pathway negatively regulates the activation of Stat5, and vice versa in breast cancer. NFAT1 interacts with Stat5 in breast cancer cells, and their physical association is mediated by the DNA binding and transactivation domains of Stat5. Ectopically expressed NFAT1 is capable of inhibiting Stat5-dependent functions, including Stat5 transactivation, Stat5-mediated transcription of the downstream target gene expression, and binding of Stat5a to the Stat5 target promoter. By contrast, overexpression of a selective NFAT inhibitor VIVIT reversed NFAT1-mediated suppression of Stat5-dependent gene expression, whereas silencing of NFAT1 through RNA interference enhanced prolactin-induced, Stat5-mediated gene transcription, and breast cancer cell proliferation. A reciprocal inhibitory effect of Stat5 activity on NFAT1 signaling was also observed, implying these two signaling cascades antagonize each other in breast cancer. Importantly, analysis of a matched breast cancer progression tissue microarray revealed a negative correlation between levels of NFAT1 and Stat5 (pY694) during the progression of breast cancer. Taken together, these studies highlight a novel negative cross talk between the NFAT1- and Stat5-signaling cascades that may affect breast tumor formation, growth, and metastasis.

Indexed as

Receptor Cross-TalkSignal TransductionBreast NeoplasmsCell Line, TumorCell ProliferationFeedback, PhysiologicalFemaleGene Expression Regulation, NeoplasticGenes, ReporterHumansLuciferases, RenillaLymphatic MetastasisLymph NodesNFATC Transcription FactorsPhosphorylationPromoter Regions, GeneticLuciferases, RenillaNFATC2 protein, humanNFATC Transcription FactorsSTAT5 Transcription Factor

Identifiers

PMID21964595
PMCPMC3231824
OpenAlexW2035427878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.